These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 17401525)

  • 1. Relationship between age and subtypes of psychotic symptoms in Parkinson's disease.
    Kiziltan G; Ozekmekçi S; Ertan S; Ertan T; Erginöz E
    J Neurol; 2007 Apr; 254(4):448-52. PubMed ID: 17401525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subthalamic nucleus stimulation for Parkinson disease with severe medication-induced hallucinations or delusions.
    Umemura A; Oka Y; Okita K; Matsukawa N; Yamada K
    J Neurosurg; 2011 Jun; 114(6):1701-5. PubMed ID: 21375379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical vignettes in Parkinson's disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours.
    Friedman JH; Agarwal P; Alcalay R; Black KJ; Chou KL; Cote L; Dayalu P; Frank S; Hartlein J; Hauser RA; Lang AE; Marsh L; Marshall F; Moskowitz C; Ravina B; Riley D; Sanchez-Ramos J; Simon DK; Simuni T; Sutton J; Tuite P; Weintraub D; Zesiewicz T
    Int J Neurosci; 2011 Aug; 121(8):472-6. PubMed ID: 21663381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive identification of delusions and olfactory, tactile, gustatory, and minor hallucinations in Parkinson's disease psychosis.
    Kulick CV; Montgomery KM; Nirenberg MJ
    Parkinsonism Relat Disord; 2018 Sep; 54():40-45. PubMed ID: 29653909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease.
    Juncos JL; Roberts VJ; Evatt ML; Jewart RD; Wood CD; Potter LS; Jou HC; Yeung PP
    Mov Disord; 2004 Jan; 19(1):29-35. PubMed ID: 14743357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose levodopa therapy in Japanese patients with Parkinson's disease: a retrospective study.
    Kitagawa M; Tashiro K
    Intern Med; 2005 Sep; 44(9):939-43. PubMed ID: 16258207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study.
    Aarsland D; Larsen JP; Cummins JL; Laake K
    Arch Neurol; 1999 May; 56(5):595-601. PubMed ID: 10328255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early dopaminergic drug-induced hallucinations in parkinsonian patients.
    Goetz CG; Vogel C; Tanner CM; Stebbins GT
    Neurology; 1998 Sep; 51(3):811-4. PubMed ID: 9748031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease.
    Merims D; Shabtai H; Korczyn AD; Peretz C; Weizman N; Giladi N
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1447-53. PubMed ID: 15480845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Othello syndrome in patients with Parkinson's disease.
    Georgiev D; Danieli A; Ocepek L; Novak D; Zupancic-Kriznar N; Trost M; Pirtosek Z
    Psychiatr Danub; 2010 Mar; 22(1):94-8. PubMed ID: 20305599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study of associated clinical variables and phenomenology of hallucinations in Parkinson's].
    Cubo E; González M; Aguilar A; Quintana S
    Neurologia; 2006; 21(1):12-8. PubMed ID: 16525921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hallucinations, delusions, and nocturnal events in 152 Parkinson's patients: a regional survey].
    Bailbé M; Karolewicz S; Neau JP; Dumas P; Gil R;
    Rev Neurol (Paris); 2002 Feb; 158(2):203-10. PubMed ID: 11965176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dilemma in Parkinson's Treatment; Levodopa Monotherapy May be the Best Choice.
    Abbasi MH; Esmaeili S; Habibi SA; Shahidi GA
    J Clin Neurosci; 2020 Sep; 79():219-223. PubMed ID: 33070900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease.
    Giladi N; Treves TA; Paleacu D; Shabtai H; Orlov Y; Kandinov B; Simon ES; Korczyn AD
    J Neural Transm (Vienna); 2000; 107(1):59-71. PubMed ID: 10809404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa-induced psychosis: a kindling phenomenon.
    Moskovitz C; Moses H; Klawans HL
    Am J Psychiatry; 1978 Jun; 135(6):669-75. PubMed ID: 655276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hallucinations in Parkinson's disease--a study of forty three patients.
    Gupta M; Singh G; Khwaja GA; Mehndiratta MM
    J Assoc Physicians India; 2004 Sep; 52():703-6. PubMed ID: 15839446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hallucinations in Parkinson's disease].
    Moser A; Hagenah J; Kömpf D
    Nervenarzt; 2003 Apr; 74(4):376-85, quiz 385-6. PubMed ID: 12707709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson's Disease.
    Haaxma CA; Horstink MW; Zijlmans JC; Lemmens WA; Bloem BR; Borm GF
    J Parkinsons Dis; 2015; 5(4):847-53. PubMed ID: 26444087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.